Angel Biotechnology

GMP contract with Novolytics

RNS Number : 5247W
Angel Biotechnology Holdings Plc
12 June 2008



12 JUNE 2008


('Angel' or 'the Company')


Angel and Novolytics announce GMP Contract for Phase I/II clinical trials

Angel Biotechnology Holdings plc, (AIM: ABH) the biopharmaceutical contract manufacturer, is pleased to announce a GMP Manufacturing deal with Novolytics Limited. Terms of the contract have not been disclosed.

Under the contract, Angel will manufacture and supply GMP materials for use in a bacteriophage based MRSA prophylactic treatment as part of a Phase I/II clinical trial scheduled to commence in 2009. The GMP production project will be carried out over a period of seven months at Angel's facilities in Edinburgh.

Commenting on the contract, Gordon Sherriff, Angel's Chief Operating Officer said: 'We are delighted to have been selected by Novolytics to be its manufacturing partner.  This is a significant project for Angel. The specialist nature of the work draws on Angel's core expertise in finding GMP solutions for such projects. The project fits well with Angel's strategic direction and will further enhance our reputation in this new and exciting field.' 

Sandy Primrose, Chief Executive Officer of Novolytics said: 'The commencement of this GMP manufacture collaboration with Angel is an important milestone in Novolytic's history. We look forward to working with Angel on this project as we move towards clinical trials.'

For further information, please call:

Angel Biotechnology Holdings plc

Tel: +44 (0) 131 445 6077

Gordon Sherriff - COO

Tel: +44 (0) 7951 057016

Grant Thornton Corporate Finance

Philip Secrett, Colin Aaronson

Tel+44 (0) 20 7383 5100 


About Angel Biotechnology Holdings plc

Angel Biotechnology Holdings plc is a biomanufacturing company offering process development services and GMP manufacturing to support biotechnology and pharmaceutical companies worldwide.  Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines.  Angel is managed by a team with wide ranging experience in biopharmaceutical manufacture, gained in companies such as Glaxo, Serologicals Inc. and PPL Therapeutics.

Angel was admitted to trading on AIM in November 2005.

More information at

About Novolytics Limited

Novolytics was formed in 2002 as a spin-out from the University of WarwickCoventryUK, to exploit the results of research into the use of natural bacteriophages to combat bacterial infection (phage therapy). In particular, Novolytics is using bacteriophage to combat hospital acquired infections with it first product targeted at preventing nasal transmission of MRSA.

Further information on Novolytics and its products can be found at 

This information is provided by RNS
The company news service from the London Stock Exchange